You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 263 No. 16, April 25, 1990 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (14)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Blood and Plasma Donations Among a Cohort of Intravenous Drug Users

Kenrad E. Nelson, MD; David Vlahov, PhD; Joseph Margolick, MD, PhD; Marie Bernal; Ellen Taylor

JAMA. 1990;263(16):2194-2197.


Abstract

We evaluated the blood and plasma donation histories of a cohort of 2921 intravenous drug users in Baltimore, Md, and correlated these histories with their human immunodeficiency virus (HIV) serologic status, numbers of CD4 lymphocytes in the peripheral blood, and stigmata of intravenous drug use (scarred veins). Of the 793 intravenous drug users (27.1%) who had donated blood or plasma, 652 (82.2%) donated after they had started using intravenous drugs. Most subjects donated at commercial plasma centers, where they were paid $10 to $15 per donation. Although the HIV-1 seroprevalence of the entire cohort was 24.1%, the HIV-1 seroprevalence among those reporting plasma or blood donations declined progressively with time, from 17.1% in those who last donated in 1985 to 3.6% in those who last donated in 1988-1989. Many of the 437 intravenous drug users who had donated plasma or blood since 1985, when screening for HIV-1 was initiated, had not been notified and counseled about their HIV test results. Current programs to exclude individuals with a history of intravenous drug use from the plasma donor pool should be reevaluated and improved.

(JAMA. 1990;263:2194-2197)



Author Affiliations

From the Departments of Epidemiology (Drs Nelson and Vlahov and Mss Bernal and Taylor) and Environmental Health Sciences (Dr Margolick), The Johns Hopkins School of Hygiene and Public Health, Baltimore, Md.


Footnotes

Preliminary results of this study were presented at the Fifth International Conference on AIDS, Montreal, Canada, June 5, 1989.

Reprint requests to Department of Epidemiology, Infectious Diseases Program, The Johns Hopkins University School of Hygiene and Public Health, Room 884, 624 N Broadway St, Baltimore, MD 21205 (Dr Nelson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Geographic Location of Commercial Plasma Donation Clinics in the United States, 1980-1995
James and Mustard
AJPH 2004;94:1224-1229.
ABSTRACT | FULL TEXT  

Achieving self sufficiency in blood across Europe
Leikola
BMJ 1998;316:489-490.
ABSTRACT | FULL TEXT  

Transmission of Retroviruses from Seronegative Donors by Transfusion during Cardiac Surgery: A Multicenter Study of HIV-1 and HTLV-I/II Infections
Nelson et al.
ANN INTERN MED 1992;117:554-559.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.